All Blogs / Health / Diseases & Conditions / Multiple Sclerosis / New

In Ongoing Phase 2 Trial, Ublituximab Seen to Effectively and Safely Deplete B-cells

TG Therapeutics’ investigational treatment — ublituximab (TG-1101) — led to a near total depletion of B-cells in patients with relapsing forms of multiple sclerosis (MS) taking part in an ongoing Phase 2 trial, the company recently announced. Show More Summary

10 Tips for a ‘Common Sense Approach’ to Life With a Chronic Illness

While living with a chronic illness can be challenging, there are ways that you can make life easier and live a happy and fulfilling life. Establishing good habits and routines takes time, but as Gunnar Esiason points out in his blog Own...Show More Summary

Another Way to Serve My Country

I first experienced MS symptoms in the fall of 2001 while I was stationed at Grand Forks Air Force Base as the senior protestant chaplain. When my primary care manager at Grand Forks suggested MS as a possibility, I started researching the disease, but all of my tests were inconclusive. Show More Summary

MS, Religion, and Spirituality: Why I Believe In God

Religion and spirituality are personal, delicate issues for many. Various schools of thought exist, and I haven’t the desire or the ability to deem one more important than the other. Writing about religious and spiritual matters is at times taboo in an often secular world. Show More Summary

If My MRI Is Stable, Why Is My Walking Getting Worse?

During a routine exam with my neurologist recently, I asked her a question I’d never thought to ask before: “Why do you order regular MRIs of my brain, but not of my spine?” Interestingly, within a few days of my exam, a Harvard MedShow More Summary

How My Life With MS Resembles the Flight of a Songbird

I don’t have a problem falling with my MS; I fall, I get back up, no problem … except, of course, when the fall is the problem. But I try to focus on the time in between the literal and figurative multiple sclerosis (MS) falls in my life. Cherishing My Time Between Falls A slow stretch of the […]

Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing Multiple Sclerosis

Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment. The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the European Commission approve the tablets. Show More Summary

Tysabri Shows Long-term Safety, Efficacy in Japanese RRMS Patients, Study Shows

A recent study has found Tysabri (natalizumab) treatment for two years to be efficient and safe in Japanese patients with relapsing-remitting multiple sclerosis (RRMS). The study, “Safety and Efficacy of Natalizumab in Japanese Patients...Show More Summary

Dealing With the Unpredictability of Multiple Sclerosis

In this video from Roche, multiple sclerosis (MS) patient and advocate Shana and her partner Leo talk about the unpredictability of the condition. Shana explains that no two days are the same when you’re living with the disease. MORE: Eight tips for dealing with the heat when you have MS. Show More Summary

MS News That Caught My Eye This Week: Brain Scans, Spasticity, Tecfidera Study and Cigarettes

In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Harvard Study Finds No Link Between Clinical Exams and MRIs in Some MS Patients I’m really not surprised at this,...Show More Summary

MSAA Unveils New Print, Online Resources for Multiple Sclerosis Patients

The Multiple Sclerosis Association of America (MSAA) has released three new resources for people with multiple sclerosis (MS), available for free as both printed and online versions on MSAA’s website. According to a press release, the...Show More Summary

RRMS Patients at Risk of PML Can Safely Switch from Tysabri to Lemtrada

Lemtrada (alemtuzumab) may be an effective option for relapsing-remitting multiple sclerosis (RRMS) patients withdrawing from prior treatment with Tysabri (natalizumab), an Italian study shows. The study, “High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study,” appeared in the journal Neurology and Therapy. Show More Summary

Olympic Soccer Star to Become an Advocate for Multiple Sclerosis

Canadian soccer star Christine Sinclair has pledged to become more involved in raising awareness for multiple sclerosis (MS). The 34-year-old, who is captain of the Canadian national team and plays club soccer in Oregon for the Portland...Show More Summary

So Tired of This

It’s summer in the U.K., and it’s hot. That’s cause for celebration for everyone but us. It’s actually the hottest June day since 1986. Heat immediately spikes my fatigue. For some of us, the cold does the same. Thankfully, not me — I get the winter off. Show More Summary

Nurse Advocates for Shared Decision-Making to Treat MS

Shared decision-making between patients and their doctors and healthcare providers was considered a critical step in the process of treating multiple sclerosis (MS), according to an article published in the journal Practical Neurology. Show More Summary

Tecfidera Improves MS Patients’ Work Productivity, Compared with Other Therapies, Study Shows

Multiple sclerosis patients taking Tecfidera, or dimethyl fumarate, were more productive at work than those on Copaxone or beta-interferon therapies, according to a study. Tecfidera also increased patients’ quality of life, researchers said. Show More Summary

Hyperosmia: My MS Makes Smells Smell … a Lot

Hyperosmia refers to an abnormally heightened sense of smell or abnormal sensitivity to odors. On the website PatientsLikeMe, where some 500,000 people have shared their personal experiences of living with a chronic condition, only about 120 of them report hyperosmia. Many of those reporting it have multiple sclerosis (MS), while others have ALS (amyotrophic lateral […]

Genentech to Report on Ocrevus Success in Reducing Disease Progression in Relapsing and Primary Progressive MS at EAN Congress

Ocrevus (ocrelizumab) significantly reduces disease activity and disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive MS (PPMS), according to results of post-hoc analyses of Genentech’s Phase 3 clinical trial program assessing the drug. Show More Summary

Ocrevus, Hope, and a Suicide Postponed

Several months ago, I wrote a column about Andrew Barclay. Barclay died in an assisted suicide in December. He’d had multiple sclerosis for many years. Colin Campbell is a 56-year-old MS patient who lives in Inverness, Scotland. He also wanted to die. Show More Summary

Copyright © 2015 Regator, LLC